Long-term treatment of hypercholesterolemia with colestipol hydrochloride.
Colestipol hydroxhloride (15 gm/day) (an anion exchange resin that binds bile acids) of placebo was administered to 92 patients with hypercholesterolemia who were followed for periods up to 36 months. There was a prompt (1 month), significant (p smaller than 0.05 minus 0.001), and sustained (36 months) lowering of serum cholesterol in the colestipol HCl-treated group, but no significant change in the placebo group. Serum triglycerides increased in both treatment groups in parallel; the reason was not apparent. Side effects were equally distributed between colestipol HCl and placebo and were primarily gastrointestinal (upper abdominal distress, constipation). Colestipol HCl appears to be a safe and effective treatment for hypercholesterolemia; tolerance does not seem to develop.
D000328:Adult; D000368:Aged; D002482:Cellulose / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D004361:Drug Tolerance; D004988:Ethers, Cyclic / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011073:Polyamines / Q000009:adverse effects / Q000627:therapeutic use*; D011108:Polymers / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D004988:Ethers, Cyclic; D010919:Placebos; D011073:Polyamines; D011108:Polymers; D014280:Triglycerides; D002482:Cellulose; D002784:Cholesterol